Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. 2004

Herman J Bueving, and Roos M D Bernsen, and Johan C de Jongste, and Lisette W A van Suijlekom-Smit, and Guus F Rimmelzwaan, and Albert D M E Osterhaus, and Maureen P M H Rutten-van Mölken, and Siep Thomas, and Johannes C van der Wouden
Department of General Practice, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands.

There is little evidence that influenza vaccination reduces asthma exacerbations. We determined whether influenza vaccination is more effective than placebo in 6-18-year-old children with asthma. We performed a randomized, double-blind, placebo-controlled trial. Parenteral vaccination with inactivated influenza vaccine or placebo took place approximately November 1, and children were followed until April 1 of the next year. Airway symptoms were reported in a diary. When symptom scores reached a predefined level, a pharyngeal swab was taken. Primary outcome was the number of asthma exacerbations associated with virologically proven influenza infection. Three hundred forty-nine children were assigned placebo, and 347 were assigned vaccine. Pharyngeal swabs positive for influenza were related to 42 asthma exacerbations, 24 in the vaccine group and 18 in the placebo group, a difference of 33% favoring placebo (31% after adjustment for confounders; 95% confidence interval, -34% to 161%). Influenza-related asthma exacerbations were of similar severity in both groups; they lasted 3.1 days shorter in the vaccine group (95% confidence interval, -6.2 to 0.002 days, p = 0.06). We conclude that influenza vaccination did not result in a significant reduction of the number, severity, or duration of asthma exacerbations caused by influenza. Additional studies are warranted to justify routine influenza vaccination of children with asthma.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D009980 Influenza A virus The type species of the genus ALPHAINFLUENZAVIRUS that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces. Alphainfluenzavirus influenzae,Avian Orthomyxovirus Type A,FLUAV,Fowl Plague Virus,Human Influenza A Virus,Influenza Virus Type A,Influenza Viruses Type A,Myxovirus influenzae-A hominis,Myxovirus influenzae-A suis,Myxovirus pestis galli,Orthomyxovirus Type A,Orthomyxovirus Type A, Avian,Orthomyxovirus Type A, Human,Orthomyxovirus Type A, Porcine,Pestis galli Myxovirus,Fowl Plague Viruses,Influenza A viruses,Myxovirus influenzae A hominis,Myxovirus influenzae A suis,Myxovirus, Pestis galli,Myxoviruses, Pestis galli,Pestis galli Myxoviruses,Plague Virus, Fowl,Virus, Fowl Plague
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D015164 Vaccines, Inactivated Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins. Inactivated Vaccine,Killed Vaccine,Killed Vaccines,Vaccines, Killed,Inactivated Vaccines,Vaccine, Inactivated,Vaccine, Killed

Related Publications

Herman J Bueving, and Roos M D Bernsen, and Johan C de Jongste, and Lisette W A van Suijlekom-Smit, and Guus F Rimmelzwaan, and Albert D M E Osterhaus, and Maureen P M H Rutten-van Mölken, and Siep Thomas, and Johannes C van der Wouden
November 2021, Circulation,
Herman J Bueving, and Roos M D Bernsen, and Johan C de Jongste, and Lisette W A van Suijlekom-Smit, and Guus F Rimmelzwaan, and Albert D M E Osterhaus, and Maureen P M H Rutten-van Mölken, and Siep Thomas, and Johannes C van der Wouden
October 2009, Journal of alternative and complementary medicine (New York, N.Y.),
Herman J Bueving, and Roos M D Bernsen, and Johan C de Jongste, and Lisette W A van Suijlekom-Smit, and Guus F Rimmelzwaan, and Albert D M E Osterhaus, and Maureen P M H Rutten-van Mölken, and Siep Thomas, and Johannes C van der Wouden
December 1994, JAMA,
Herman J Bueving, and Roos M D Bernsen, and Johan C de Jongste, and Lisette W A van Suijlekom-Smit, and Guus F Rimmelzwaan, and Albert D M E Osterhaus, and Maureen P M H Rutten-van Mölken, and Siep Thomas, and Johannes C van der Wouden
September 1999, Annals of internal medicine,
Herman J Bueving, and Roos M D Bernsen, and Johan C de Jongste, and Lisette W A van Suijlekom-Smit, and Guus F Rimmelzwaan, and Albert D M E Osterhaus, and Maureen P M H Rutten-van Mölken, and Siep Thomas, and Johannes C van der Wouden
October 1994, Vaccine,
Herman J Bueving, and Roos M D Bernsen, and Johan C de Jongste, and Lisette W A van Suijlekom-Smit, and Guus F Rimmelzwaan, and Albert D M E Osterhaus, and Maureen P M H Rutten-van Mölken, and Siep Thomas, and Johannes C van der Wouden
February 1996, Annals of emergency medicine,
Herman J Bueving, and Roos M D Bernsen, and Johan C de Jongste, and Lisette W A van Suijlekom-Smit, and Guus F Rimmelzwaan, and Albert D M E Osterhaus, and Maureen P M H Rutten-van Mölken, and Siep Thomas, and Johannes C van der Wouden
December 2008, The Journal of pediatrics,
Herman J Bueving, and Roos M D Bernsen, and Johan C de Jongste, and Lisette W A van Suijlekom-Smit, and Guus F Rimmelzwaan, and Albert D M E Osterhaus, and Maureen P M H Rutten-van Mölken, and Siep Thomas, and Johannes C van der Wouden
September 2010, Respiratory medicine,
Herman J Bueving, and Roos M D Bernsen, and Johan C de Jongste, and Lisette W A van Suijlekom-Smit, and Guus F Rimmelzwaan, and Albert D M E Osterhaus, and Maureen P M H Rutten-van Mölken, and Siep Thomas, and Johannes C van der Wouden
January 1998, Vaccine,
Herman J Bueving, and Roos M D Bernsen, and Johan C de Jongste, and Lisette W A van Suijlekom-Smit, and Guus F Rimmelzwaan, and Albert D M E Osterhaus, and Maureen P M H Rutten-van Mölken, and Siep Thomas, and Johannes C van der Wouden
January 2019, Advanced journal of emergency medicine,
Copied contents to your clipboard!